

Virginia Medicaid
Pharmacy & Therapeutics Committee Meeting
Agenda
600 East Broad Street – 7th Floor Conference Rooms
Richmond, VA 23219
April 24, 2014 – 10 AM

Welcome and Comments

Cindi Jones, Director

Call to Order

Tim Jennings, Pharm.D, Chair

Drug Utilization Review (DUR) Board Report

Avtar Dhillon, M.D., DMAS DUR Board

Magellan Medicaid Administration Update

Debbie Moody, RPh, Clinical Manager

Approval of Minutes from October 24, 2013 Meeting

P&T Committee Members

PDL Management

P&T Committee Members

- **Old Business**
 - Update on ADHD drugs prescribed for non-FDA approved ages
 - Narcotic Utilization – report “normalized” for members per prescriber
 - Prescription Monitoring Program (PMP)
 - Policies in Other States
 - Update on new service authorization requirement to include PMP documentation
- **PDL Phase I – New Drug Review (*Therapeutic Class*)**
 - Epaned[™] 1 mg/mL oral solution (*Angiotensin-Converting Enzyme Inhibitor*)
 - Aerospan[™] (flunisolide) (*Glucocorticoids, Inhaled*)
 - Olysio[™] (simeprevir) & Sovaldi[™] (sofosbuvir) (*Hepatitis C Agents*)
 - Niacin ER (*Niacin Derivatives*)
 - Gatifloxacin 0.5% Ophthalmic Solution (*Ophthalmic Antibiotics*)
 - Adempas[®] & Opsumit[®] (*PAH Agents*)
 - Velphoro[®] chewable tablet (*Phosphate binder*)
 - Aciphex[®] Sprinkle, esomeprazole strontium & rabeprazole delayed-release tab (*Proton Pump Inhibitors*)
 - Tolterodine ER (*Urinary Antispasmodics*)
- **PDL Phase II – Annual Review (*Therapeutic Class*)**
 - **Analgesics**
 - Barbiturate & Non-salicylate Analgesics (*and combinations*)
 - Narcotics (*includes long acting, short acting, combinations, and lozenges*)
 - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (*includes Cox-2 inhibitors*)
 - Opioid Analgesics & Dependency
 - Topical Agents & Anesthetics
 - **Antibiotics/Anti-infectives**
 - 2nd and 3rd Generation Cephalosporins
 - 2nd and 3rd Generation Quinolones (systemic)
 - Ketolides & Macrolides (adult and pediatric)
 - Oral Antifungals
 - Otic Quinolones
 - Topical Antibiotics

- **PDL Phase II – Annual Review (*continued*)**
 - ***Antivirals***
 - Antivirals for the Treatment of Herpes or Influenza
 - Topical Antivirals
 - ***Bone Resorption Suppression and Related Agents***
 - Bisphosphonates
 - Calcitonins
 - Others
 - ***Cardiac Medications***
 - Anticoagulants (*includes low molecular weight heparins, Factor XA inhibitors and oral anticoagulants*)
 - Platelet Inhibitors
 - ***Central Nervous System***
 - Antihyperkinesis/CNS Stimulants
 - Antimigraine
 - Non-Ergot Dopamine Receptor Agonists
 - Skeletal Muscle Relaxants
 - Smoking Cessation
 - ***Dermatologic***
 - Acne Agents (*includes benzoyl peroxide, clindamycin, topical retinoids & combinations*)
 - Topical Agents For Psoriasis
 - ***Endocrine and Metabolic Agents***
 - Androgenic Agents
 - Antihyperuricemics
 - Contraceptives (*oral, vaginal & transdermal*)
 - Erythropoiesis Stimulating Proteins
 - Injectable Hypoglycemics (*includes insulins, incretin mimetics, GLP-1 receptor agonists*)
 - Oral Hypoglycemics (*includes 2nd generation sulfonylureas, alpha-glucosidase inhibitors, biguanides, biguanide combinations, meglitinides, thiazolidinediones, DPP-IV inhibitors and combinations*)
 - Progestational Agents
 - Vaginal Estrogens
 - ***Gastrointestinal***
 - Motility Agents – GI Stimulants (*This class was moved to the fall meeting and covered as part of Antiemetic/Antivertigo Agents*)
 - ***Immunologic Agents***
 - Multiple Sclerosis Agents
 - Self Administered Drugs for Rheumatoid Arthritis

Confidential Meeting (Pricing Information Discussion)

P&T Committee Members & DMAS Staff

Criteria Discussion of Phase I New Drugs

P&T Committee Members

Criteria Discussion of Phase II New Drugs

P&T Committee Members

Next Meeting – October 16, 2014 (tentative)

Chair

Oral Presentations: The P&T Committee in conjunction with the Department will be allocating time slots for interested parties to present scientific and clinical information on **only** the drug classes in Phase II which are scheduled

for review at the April meeting and new drugs in PDL Phase I listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Phase II Annual Review – April 2013 to present
- New Drugs in PDL Phase I Drug Classes – April 2012 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 3 minutes to present. The actual speakers will be decided by the Chairperson based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter. Please send information to pdlinput@dmas.virginia.gov and dfmoody@magellanhealth.com by 5 p.m. EST on **Thursday, April 2, 2014.**